PET STUDIES OF THE DOPAMINE TRANSPORTER IN ADULT ADHD

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。多动症是一种常见的神经精神疾病，影响了3-7%的学龄儿童和1-5%的成年人。精神运动兴奋剂药物，如安非他明，是主要的治疗方法。临床前数据表明，安非他明可能损害动物的多巴胺能神经元。此外，现在有证据表明，在狒狒和松鼠猴身上，相当于治疗多动症的安非他明剂量会导致多巴胺神经毒性。本研究的目的是通过PET检测多巴胺转运体的放射性配体[11C]WIN3652和水泡状单胺转运体的放射性配体[11C]DTBZ，来评估成人ADHD患者脑多巴胺能神经元的状态。研究人员假设，与未接受安非他明治疗的成年人相比，接受安非他明治疗的ADHD患者两种多巴胺标记物都有所减少。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. ADHD is a common neuropsychiatric disorder that affects 3-7% of school age children and 1-5% of adults. Psychomotor stimulant drugs such as amphetamine are the mainstay of therapy. Preclinical data have suggested that amphetamine may damage dopaminergic neurons in animals. Moreover, there is now evidence in baboons and squirrel monkeys that amphetamine doses equivalent to those used treat ADHD lead to dopamine neurotoxicity. The purpose of this study is to assess the status of brain dopaminergic neurons in adults with ADHD using PET with [11C]WIN3652, a radioligand selective for the dopamine transporter, and [11C]DTBZ, a radioligand selective for the vesicular monoamine transporter. The investigators hypothesize that adults with ADHD treated with amphetamines will have reductions in both dopamine markers compared to adults who have not previously received amphetamines.